Clinical trial · no report yet · Phase 3
ASCENT-07
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
- NCT05840211 ↗
- Active not recruiting
- Gilead Sciences
- 74 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 33 | |
| YouTube | 26 | |
| Podcasts | 14 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer
- Interventions
- Sacituzumab Govitecan-hziy; Paclitaxel; Nab-paclitaxel; Capecitabine
- Arms
- Sacituzumab Govitecan-hziy (SG) · Experimental
- Treatment of Physician's Choice (TPC) · Active comparator
- Enrollment
- 654 (estimated)
- Primary outcomes
- Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
- Sponsor
- Gilead Sciences
- Start
- May 8, 2023
- Primary completion
- Apr 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05840211 · updated Oct 3, 2025
Publications
linked from the registry- Tarantino P, Tolaney SM, Curigliano G. Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment. Ann Oncol. 2023 Oct;34(10):949-950. doi: 10.1016/j.annonc.2023.07.003. Epub 2023 Jul 26. No abstract available. PubMed 37499870